Cassava Sciences Inc reports results for the quarter ended in September 30 - Earnings Summary

Filana Therapeutics

07/11/2024 14:29

* Cassava Sciences Inc  SAVA.OQ  reported a quarterly
adjusted
loss of 58 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -61 cents.  The mean expectation of two analysts
for the quarter was for a loss of 88 cents per share. Wall
Street expected results to range from $-1.37 to -39 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cassava Sciences Inc's reported EPS for the quarter was a
loss
of 58 cents​.
    * The company reported a quarterly loss of $27.94 million.
    * Cassava Sciences Inc shares had fallen by 9.7% this
quarter and
gained 18.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 107.1% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Cassava Sciences
Inc is 116.00 
This summary was machine generated from LSEG data November 7 at
02:28 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.88          -0.58          Beat
 Jun. 30 2024      -0.40          0.13           Beat
 Mar. 31 2024      -0.46                         
 Dec. 31 2023      -0.52